Showing results 3684 to 3703 of 14621
< previous
next >
| Preview | Issue Date | Title | Author(s) |
| 2010 | Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo | Fraser, C.; Lousberg, E.; Guerin, L.; Hughes, T.; Brown, M.; Diener, K.; Hayball, J. |
| 2008 | Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications | Hiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D. |
| 2009 | Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial | Apperley, J.; Cortes, J.; Kim, D.; Roy, L.; Roboz, G.; Rosti, G.; Bullorsky, E.; Abruzzese, E.; Hochhaus, A.; Heim, D.; De Souza, C.; Larson, R.; Lipton, J.; Khoury, J.; Kim, H.; Sillaber, C.; Hughes, T.; Erben, P.; Tornout, J.; Stone, R. |
| 2009 | Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo | Fraser, C.; Blake, S.; Diener, K.; Lyons, A.; Brown, M.; Hughes, T.; Hayball, J. |
| 2009 | Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo | Fraser, C.; Lousberg, E.; Kumar, R.; Hughes, T.; Diener, K.; Hayball, J. |
| 2009 | Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R) | Kantarjian, H.; Pasquini, R.; Levy, V.; Jootar, S.; Holowiecki, J.; Hamerschlak, N.; Hughes, T.; Bleickardt, E.; Dejardin, D.; Cortes, J.; Shah, N. |
| 2013 | Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells | Hiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T. |
| 2009 | Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations | Khoury, H.; Guilhot, F.; Hughes, T.; Kim, D.; Cortes, J. |
| 2009 | Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations | Muller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A. |
| 2009 | Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value | Hochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T. |
| 2018 | Data mining of small RNA-Seq suggests an association between prostate cancer and altered abundance of 5' transfer RNA halves in seminal fluid and prostatic tissues | Dhahbi, J.M.; Atamna, H.; Selth, L.A. |
| 2016 | Data on keratin expression in human cells cultured with Australian native plant extracts | Adams, D.; Shou, Q.; Wohlmuth, H.; Cowin, A. |
| 2016 | Data set demonstrating an absence of touch effects on social orienting in adults | Reece, C.; Ebstein, R.; Cheng, X.; Ng, T.; Schirmer, A. |
| 2009 | David Paul Hansemann: Chromosomes and the origin of the cancerous features of tumor cells | Bignold, L.; Coghlan, B.; Jersmann, H. |
| 2007 | David Paul von Hansemann: Contributions to oncology: Context, comments and translations | Bignold, L.; Coghlan, B.; Jersmann, H. |
| 2013 | Day-to-day physical functioning and disability in obese 10-to 13-year-olds | Tsiros, M.D.; Buckley, J.D.; Howe, P.R.C.; Olds, T.; Walkley, J.; Taylor, L.; Mallows, R.; Hills, A.P.; Kagawa, M.; Coates, A.M. |
| 2015 | Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors | Katz, P.; Kahrilas, P.; Johnson, D.; Lind, T.; Rohss, K.; Traxler, B.; Hugo, V.; Dent, J. |
| 2018 | Daytime loop gain is elevated in obstructive sleep apnea but not reduced by CPAP treatment | Deacon-Diaz, N.L.; Sands, S.A.; McEvoy, R.D.; Catcheside, P.G. |
| 2014 | Dbx1 is a direct target of SOX3 in the spinal cord | Rogers, N.; McAninch, D.; Thomas, P.; Alsina, B. |
| 2016 | Dclk1 defines quiescent pancreatic progenitors that promote injury-induced regeneration and tumorigenesis | Westphalen, C.; Takemoto, Y.; Tanaka, T.; Macchini, M.; Jiang, Z.; Renz, B.; Chen, X.; Ormanns, S.; Nagar, K.; Tailor, Y.; May, R.; Cho, Y.; Asfaha, S.; Worthley, D.; Hayakawa, Y.; Urbanska, A.; Quante, M.; Reichert, M.; Broyde, J.; Subramaniam, P.; et al. |
